title: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
abstract: Tumor cell invasion and metastasis is a multifactorial process, which at each step may require the action of proteolytic enzymes such as collagenases, cathepsins, plasmin, or plasminogen activators. An enzymatically inactive proenzyme form of the urokinase-type plasminogen activator (pro-uPA) is secreted by tumor cells which may be converted to an enzymatically active two-chain uPA-molecule (HMW-uPA) by plasmin-like enzymes. Action of proteases on pro-uPA may generate the enzymatically active or inactive high-molecular-weight form of uPA (HMW-uPA). Some proteases (plasmin, cathepsin B and L, kallikrein, trypsin or thermolysin) activate pro-uPA by cleaving the peptide bond Lys158 and IIe159. Other proteases (elastase, thrombin) cleave pro-uPA at different positions to yield enzymatically inactive HMW-uPA. HMW-uPA may be split into the enzymatically active LMW-uPA and the enzymatically inactive ATF (amino terminal fragment). ATF may be cleaved between peptide sequence 20 and 40 within the receptor binding domain of uPA (GFD). Such impaired ATF does not bind to uPA-receptors. Action of the bacterial endoproteinase Asp-N from Pseudomonas fragi mutant on pro-uPA or HMW-uPA, however, generates intact ATF which efficiently competes for binding of HMW-uPA or pro-uPA to receptors on tumor cells. High uPA-antigen content (pro-uPA, HMW-uPA, or LMW-uPA) in breast cancer tissue (not in plasma) indicates an elevated risk for the patient of recurrences and shorter overall survival. Thus pro-uPA/uPA-antigen content in breast cancer tissue serves as an independent prognostic parameter for the outcome of the disease. Cathepsin D is also an independent prognostic factor for recurrences and overall survival. High content of cathepsin D in breast cancer tumors is, however, not correlated with elevated levels of pro-uPA/uPA indicating that synthesis and release of cathepsin D and pro-uPA/uPA are independent events.
authors.affiliation: Frauenklinik, Technischen Universität München, Klinikum rechts der Isar, FRG.
authors.forename: M
authors.initials: M
authors.lastname: Schmitt
authors.forename: L
authors.initials: L
authors.lastname: Goretzki
authors.forename: F
authors.initials: F
authors.lastname: Jänicke
authors.forename: J
authors.initials: J
authors.lastname: Calvete
authors.forename: M
authors.initials: M
authors.lastname: Eulitz
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: N
authors.initials: N
authors.lastname: Chucholowski
authors.forename: H
authors.initials: H
authors.lastname: Graeff
mesh_terms: D001665:Binding Sites; D001943:Breast Neoplasms / Q000201:enzymology* / Q000556:secondary; D004792:Enzyme Precursors / Q000378:metabolism; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D010446:Peptide Fragments / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D011379:Prognosis; D011994:Recombinant Proteins; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
chemical_list: D004792:Enzyme Precursors; D010446:Peptide Fragments; D011994:Recombinant Proteins; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase